Add to ORKGHBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisonin
Deferasirox (ICL670) is a once-daily oral iron chelator developed for the treatment of chronic iron ...
Regular blood transfusions as supportive care for patients with chronic anemia inevitably lead to ir...
Although blood transfusions are essential for patients with hemoglobinopathies (ie Thalassemia, Sick...
To further examine the potential clinical usefulness of the hexadentate phenolic aminocarboxylate ir...
Regular blood transfusions for the treatment of chronic anemia inevitably lead to iron overload sin...
Janet L Kwiatkowski The Children's Hospital of Philadelphia, Division of Hematology and Univ...
Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron c...
Transfusion therapy for inherited anemias and acquired refractory anemias both improves the quality ...
Iron accumulation is an inevitable consequence of chronic blood transfusions and results in serious ...
Although blood transfusions are important for patients with hemoglobinopathies, chronic transfusions...
Children with severe chronic hemolytic anemia or congenital erythroblastopenia are transfusion depen...
Iron chelation therapy (ICT) has become a mainstay in heavily transfused hematological patients, wit...
Iron accumulation is an inevitable consequence of chronic blood transfusions and results in serious ...
Although blood transfusions are important for patients with anemia, chronic transfusions inevitably ...
Deferoxamine is widely used therapeutically as a chelator of ferric ion in disorders of iron overloa...
Deferasirox (ICL670) is a once-daily oral iron chelator developed for the treatment of chronic iron ...
Regular blood transfusions as supportive care for patients with chronic anemia inevitably lead to ir...
Although blood transfusions are essential for patients with hemoglobinopathies (ie Thalassemia, Sick...
To further examine the potential clinical usefulness of the hexadentate phenolic aminocarboxylate ir...
Regular blood transfusions for the treatment of chronic anemia inevitably lead to iron overload sin...
Janet L Kwiatkowski The Children's Hospital of Philadelphia, Division of Hematology and Univ...
Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron c...
Transfusion therapy for inherited anemias and acquired refractory anemias both improves the quality ...
Iron accumulation is an inevitable consequence of chronic blood transfusions and results in serious ...
Although blood transfusions are important for patients with hemoglobinopathies, chronic transfusions...
Children with severe chronic hemolytic anemia or congenital erythroblastopenia are transfusion depen...
Iron chelation therapy (ICT) has become a mainstay in heavily transfused hematological patients, wit...
Iron accumulation is an inevitable consequence of chronic blood transfusions and results in serious ...
Although blood transfusions are important for patients with anemia, chronic transfusions inevitably ...
Deferoxamine is widely used therapeutically as a chelator of ferric ion in disorders of iron overloa...
Deferasirox (ICL670) is a once-daily oral iron chelator developed for the treatment of chronic iron ...
Regular blood transfusions as supportive care for patients with chronic anemia inevitably lead to ir...
Although blood transfusions are essential for patients with hemoglobinopathies (ie Thalassemia, Sick...